Key Details
Annual ROE
-213.85%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Sept 30, 2022Recent annual earnings:
Apr 01, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with LBPS included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
4D pharma doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of 4D pharma?
- What is the ticker symbol for 4D pharma?
- Does 4D pharma pay dividends?
- What sector is 4D pharma in?
- What industry is 4D pharma in?
- What country is 4D pharma based in?
- When did 4D pharma go public?
- Is 4D pharma in the S&P 500?
- Is 4D pharma in the NASDAQ 100?
- Is 4D pharma in the Dow Jones?
- When was 4D pharma's last earnings report?
- When does 4D pharma report earnings?
What is the primary business of 4D pharma?
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.
What is the ticker symbol for 4D pharma?
The ticker symbol for 4D pharma is NASDAQ:LBPS
Does 4D pharma pay dividends?
No, 4D pharma does not pay dividends
What sector is 4D pharma in?
4D pharma is in the Healthcare sector
What industry is 4D pharma in?
4D pharma is in the Biotechnology industry
What country is 4D pharma based in?
4D pharma is headquartered in United Kingdom
When did 4D pharma go public?
4D pharma's initial public offering (IPO) was on 22 March 2021
Is 4D pharma in the S&P 500?
No, 4D pharma is not included in the S&P 500 index
Is 4D pharma in the NASDAQ 100?
No, 4D pharma is not included in the NASDAQ 100 index
Is 4D pharma in the Dow Jones?
No, 4D pharma is not included in the Dow Jones index
When was 4D pharma's last earnings report?
4D pharma's most recent earnings report was on 30 September 2022
When does 4D pharma report earnings?
The date for 4D pharma's next earnings report has not been announced yet